Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy
10.3760/cma.j.issn.0253-3766.2015.08.014
- VernacularTitle:吉西他滨联合异环磷酰胺对铂类方案化疗失败的晚期鼻咽癌患者的疗效及安全性评价
- Author:
Shaoxuan HU
1
;
Xiaohui HE
;
Mei DONG
;
Bo JIA
;
Shengyu ZHOU
;
Jianliang YANG
;
Sheng YANG
;
Changgong ZHANG
;
Peng LIU
;
Yan QIN
;
Lin GUI
Author Information
1. 100021,中国医学科学院 北京协和医学院肿瘤医院内科
- Keywords:
Nasopharyngeal neoplasms;
Drug therapy;
Gemcitabine;
Ifosfamide;
Treatment outcome;
Prognosis
- From:
Chinese Journal of Oncology
2015;(8):632-636
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen) in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum?based chemotherapy. Methods The clinical data of 27 nasopharyngeal carcinoma patients, who received GI regimen between April 2005 and March 2014 after failure of prior platinum?based chemotherapy, were retrospectively reviewed,and relevant prognostic factors were explored. Results All patients were evaluable for efficacy and toxicity. No patient achieved complete response ( CR) . Partial response ( PR) was achieved in ten patients, stable disease ( SD) in thirteen patients, progressive disease ( PD) in four patients, with a response rate of 37.0% and an overall disease control rate (PR+SD) of 85.2%. For ten PR patients, the median duration of response was 5.5 months. The median progression?free survival of the whole group was 6.7 months, and the Kaplan?Meier estimate of median overall survival was 17.4 months. The 1?year survival rate was 72.6%. Toxicity was mainly hematological: Grade Ⅲ or Ⅳ anemia, neutropenia and thrombocytopenia were found in 3.7%, 37.0% and 18.5% of all patients, respectively. Univariate and multivariate analyses indicated that dose intensity of gemcitabine was a significant prognostic factor for PFS, whereas salvage treatment after failure of GI regimen was a significant prognostic factor for OS. Conclusions Gemcitabine and ifosfamide combination is effective and well tolerated by patients with advanced nasopharyngeal carcinoma pretreated with platinum?based chemotherapy. Further clinical study is warranted.
